The 340B program needs drug makers to offer outpatient drugs at lower prices to certain healthcare providers called “covered entities.” These include some hospitals like disproportionate share hospitals, children’s hospitals, critical access hospitals, federally qualified health centers (FQHCs), and AIDS drug assistance programs.
Covered entities get 340B drugs at discounted prices from wholesalers or specialty distributors. The Health Resources and Services Administration (HRSA) sets the maximum price based on the average manufacturer price minus a rebate. Discounts usually range from 20% to 50%, helping covered entities save money on outpatient drugs. This is important when budgets are tight.
But these discounts only work if covered entities follow many rules set by HRSA’s Office of Pharmacy Affairs (OPA). Not following the rules can lead to audits, fines, and even getting kicked out of the program.
One big reason covered entities struggle with the 340B program is they don’t have enough staff to handle it. The program needs people to check who is eligible, update policies, prepare for audits, and keep data accurate.
Many facilities now hire full-time workers or hire outside companies to manage 340B compliance. These people keep the program running correctly every day. Without them, organizations risk breaking rules and losing savings.
HRSA expects covered entities to have clear written policies that match hospital or clinic rules. These policies should cover patient eligibility, stopping drug misuse, avoiding duplicate discounts, and handling contract pharmacies.
These policies also need to be checked and updated regularly. Not keeping good and current policies is a big risk in HRSA audits.
The 340B program says discounted drugs can only go to eligible patients. A “340B patient” must have a real relationship with the covered entity and get qualifying healthcare, not just a prescription.
Giving 340B drugs to patients who are not eligible, like those who just got a prescription for self-use, is a violation. Covered entities must keep exact records to prove patient eligibility. Many audits find mistakes here.
Covered entities sometimes use contract pharmacies to give 340B drugs at many places. While contract pharmacies help with access, managing them is hard. About 81% of covered entities audited in 2019 had contract pharmacies.
Every contract pharmacy must be registered with HRSA’s OPA before giving 340B drugs. Both sides must sign written agreements. Covered entities must watch these pharmacies to stop drug misuse or duplicate discounts.
Audits show many problems come from lack of oversight or missing contracts. Sometimes contract pharmacies have to be dropped. Regular audits and checking transactions help keep compliance.
Duplicate discounts happen if a drug gets both a 340B discount and a Medicaid rebate, which is not allowed. Product diversion means giving 340B drugs outside allowed rules.
HRSA audits from 2012 to 2019 found many cases of diversion and duplicate discounts. About 38% of covered entities had two or more major problems. These issues can mean paying back money and facing penalties.
It is important to keep Medicaid billing clear and records correct to avoid duplicate discounts.
Good record-keeping is very important in the 340B program, but many covered entities have data problems. Common mistakes are wrong provider files, outdated pharmacy info, and mismatched patient data like different names or birth dates.
These errors often happen because entities use many electronic health records (EHRs), third-party administrators (TPAs), and pharmacies. It can cause lost savings, rejected claims, or rule breaks.
For example, patient names like “Jim” instead of “James” may cause claim problems. Fixing these requires standard data methods and careful database updates.
Covered entities must track which health providers’ claims qualify for 340B discounts. Providers can be Exclusive/Standard, Non-Exclusive/Non-Standard, or Referral, each with different rules.
Mistakes in provider classification or not updating provider lists can lead to wrong claims or missed savings. Working closely with TPAs and setting claim systems right helps keep billing accurate and legal.
Covered entities should create clear 340B policies that fit with their hospital or clinic rules. These policies should cover patient eligibility, contract pharmacy deals, avoiding duplicate discounts, inventory control, and audit steps.
Regular staff training helps everyone know the rules and their duties. HRSA and contractors like Apexus offer useful training materials.
Using special 340B software helps keep provider files, billing info, pharmacy registrations, and drug inventory correct. These systems track data in real time and make reports needed for compliance.
Advanced inventory systems can count stock, watch dispensing patterns, and mark prescriptions, which lowers mistakes seen in manual work.
Doing regular audits on contract and in-house pharmacies is a good practice. These reviews find problems early so fixes can happen before HRSA or manufacturer audits.
Setting up a 340B governance committee helps monitor and manage responsibilities. These groups meet often to check policies, audit results, data quality, and problems.
Hiring experts in contract pharmacy management can improve compliance.
Keep provider lists accurate and updated. This means clear start dates, National Provider Identifiers (NPIs), service areas, and provider types.
Patient data accuracy, like names and birth dates, is just as important to avoid claim denials and compliance problems. Standard data entry and teamwork between EHRs and TPAs help reduce errors.
HRSA does about 200 audits every year to check 340B compliance. Covered entities should prepare audit packets including eligibility records, pharmacy contracts, drug purchase data, billing info, policies, and self-audit results.
If audits find problems, covered entities must quickly tell manufacturers, offer correction plans, and send detailed reports to HRSA. Early communication and fixing issues can reduce penalties.
Artificial intelligence (AI) and workflow automation are becoming more important to help manage the 340B program. These tools help healthcare administrators run the program more easily and accurately.
AI can automatically review large amounts of data from EHRs, pharmacy systems, and billing platforms. It finds errors in patient eligibility, provider data mismatches, and possible duplicate discounts or diversion.
For example, natural language processing can read provider notes or referral paperwork to confirm patient eligibility. This lowers the need for manual checks and improves accuracy.
Automation tools track contract pharmacy registrations, notice pharmacy ownership changes, and update the HRSA OPA system on time. Alerts notify compliance teams about expiring contracts or needed renewals.
AI algorithms also keep provider lists accurate by watching provider changes like status, location, or service area to stop claim errors.
The 340B program needs careful tracking of refunds when overcharges happen. AI systems manage communication with drug makers, calculate refund amounts correctly, and schedule payments automatically.
Audit prep is easier with document systems that collect needed files and make audit reports. This helps staff meet deadlines and follow rules.
AI-based training can create personalized lessons for staff based on their jobs, past training, and areas needing improvement. Automated compliance dashboards show real-time program status and alert about issues like policy updates, audit problems, or contract renewals.
These tools help administrators and IT managers keep watch on the program without manual tracking.
Medical practice managers, owners, and IT staff in the United States should understand how complex the 340B program is and manage it carefully. Knowing the rules, using dedicated staff, and adopting AI tools can reduce risks and keep benefits. This helps covered entities serve low-income and vulnerable patients well.
The 340B Drug Pricing Program was created in 1992 by Congress to provide safety-net providers discounts on outpatient drugs, enabling them to extend federal resources to provide more comprehensive services to vulnerable populations.
Eligible entities include various hospitals (e.g., disproportionate share hospitals, critical access hospitals) and non-hospital entities like federally qualified health centers, AIDS drug assistance programs, and more.
The program is administered by the Office of Pharmacy Affairs (OPA) within the Health Resources and Services Administration (HRSA) under HHS.
Entities can apply by completing the online registration process during the first two weeks of any calendar quarter, and approved entities are listed in the 340B OPA Information System.
Covered entities must decide whether to ‘carve in’ or ‘carve out’ 340B drugs for Medicaid fee-for-service patients, ensuring compliance with duplicate discount prohibitions to avoid overcharging.
Compliance is ensured through annual recertification, monitoring contract pharmacies, and establishing criteria for reporting breaches of compliance to HRSA.
Common pitfalls include improper billing practices, failure to monitor contract pharmacies, and inadequate documentation of patient eligibility.
Violating the ceiling price results in penalties, including refunding overcharges and potential civil monetary penalties for knowing violations.
Yes, covered entities can contract with pharmacies but must ensure compliance with 340B requirements, including tracking patient eligibility and preventing diversion.
HRSA conducts audits of covered entities, with approximately 200 audits per year, and manufacturers can also audit but must do so under specific HRSA guidelines.
Simbo is using AI agents to automate all phone related workflows. Connect now to know more.
Schedule AI Agents Demo Now© Since 2019, Simbo AI.
